REG
The subscription period in PILA PHARMA's rights issue of units begins today
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
PILA PHARMA DISCUSSES ITS FINANCING ROUND WITH HELGE LARSEN & PROINVESTOR
PILA PHARMA AB (publ) (FN STO: PILA) has the pleasure to share with investors and others with interest in the Company or the general market, that PILA PHARMA has had another 1-on...
THE LAST DAY OF TRADING IN PILA PHARMA'S SHARES INCLUDING THE RIGHT TO RECEIVE UNIT RIGHTS
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
REG
PILA PHARMA PUBLISHES PROSPECTUS IN CONNECTION WITH THE ANNOUNCED RIGHTS ISSUE OF UNITS
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
REG
MAR
THE BOARD OF DIRECTORS OF PILA PHARMA HAS RESOLVED TO CARRY OUT A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 20 MILLION
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
PILA PHARMA: ALL INVESTOR PRESENTATION RECORDINGS NOW ONLINE
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA VISITED DIREKT STUDIOS' INVESTMENT CHANNEL
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today informs inv...
PILA PHARMA PARTICIPATED IN INVESTMENT PODCAST 10X
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA INVITES TO AFTER-WORK MINGLE IN STOCKHOLM
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, hereby invites in...
PILA PHARMA UPCOMING INVESTOR PRESENTATIONS IN STOCKHOLM
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, hereby invites in...
PILA PHARMA DISCUSSED ITS POTENTIAL ROLE IN OBESITY & DIABETES WITH HELGE LARSEN & PROINVESTOR
PILA PHARMA AB (publ) (FN STO: PILA) has the pleasure to share with investors and others with interest in the Company or the general market, that PILA PHARMA had a 1-on-1 intervi...
PILA PHARMA TO RE-VISIT PROINVESTOR WITH HELGE LARSEN TO DISCUSS THE COMPANY'S AMBITIONS IN OBESITY & DIABETES
PILA PHARMA AB (publ) (FN STO: PILA) today informs investors and others with interest in the Company, that PILA PHARMA will be going back to participate for a 1-on-1 interview wi...
REG
MAR
PILA PHARMA PROACTIVELY MOVES FORWARD WITH PP-CT03 CLINICAL TRIAL APPLICATION FOR STUDY IN PEOPLE LIVING WITH OBESITY AND DIABETES
PILA PHARMA AB (publ) (FN STO: PILA) today informs the continuation of preparations for the clinical trial application for PP-CT03, a pivotal and pioneering 12-week Phase 2a stud...
REG
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2025
PILA PHARMA AB (publ) höll på torsdagen den 29 april 2025 årsstämma hos MAQS Advokatbyrå, Gibraltargatan 7 i Malmö. Följande huvudsakliga beslut fattades:Fastställande av resulta...
PILA PHARMA UPCOMING INVESTOR MEETINGS
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites investors and others with interest in the Company, to meet PILA PHARMA at these upcoming events:
Malmömorgon (Slagthuset, Mal...
PILA PHARMA: REMINDER - LAST DAY FOR SHAREHOLDER REGISTRATION FOR ANNUAL GENERAL MEETING
PILA PHARMA AB (publ) (FN STO: PILA) today reminds shareholders that today, 23 April is the last day to register attendance at this year's Annual General meeting.
PILA PHARMA wel...
REG
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB
Aktieägarna i PILA PHARMA AB (publ), org.nr 556966-4831, ("PILA PHARMA" eller "Bolaget") kallas härmed till årsstämma tisdag den 29 april 2025, kl. 15.00 i MAQS Advokatbyrås loka...
REG
PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024
PILA PHARMA AB (publ) (FN STO: PILA) announces that the annual report (in Swedish) is now available on the Company´s homepage, https://pilapharma.com/investors/finansiell-informa...
Om PILA PHARMA
Webbplats
pilapharma.com
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs ()
Förändring ()